an approach to “bad blood” aka acute leukemia arif ali awan – r2 jgh november 27 th, 2014 im...
TRANSCRIPT
![Page 1: AN APPROACH TO “BAD BLOOD” AKA ACUTE LEUKEMIA Arif Ali Awan – R2 JGH November 27 th, 2014 IM Teaching](https://reader035.vdocuments.us/reader035/viewer/2022062712/56649c7b5503460f9492e944/html5/thumbnails/1.jpg)
AN APPROACH TO “BAD BLOOD” AKA
ACUTE LEUKEMIA
Arif Ali Awan – R2 JGHNovember 27th, 2014IM Teaching
![Page 2: AN APPROACH TO “BAD BLOOD” AKA ACUTE LEUKEMIA Arif Ali Awan – R2 JGH November 27 th, 2014 IM Teaching](https://reader035.vdocuments.us/reader035/viewer/2022062712/56649c7b5503460f9492e944/html5/thumbnails/2.jpg)
DISCLAIMER
Just a Resident
![Page 3: AN APPROACH TO “BAD BLOOD” AKA ACUTE LEUKEMIA Arif Ali Awan – R2 JGH November 27 th, 2014 IM Teaching](https://reader035.vdocuments.us/reader035/viewer/2022062712/56649c7b5503460f9492e944/html5/thumbnails/3.jpg)
CASE
52F Nurse, 3 sisters
PMHx: HTN, hysterectomy
Meds: Hctz 12.5; NKDA
No family history
Presents with 6 week history of intermittent fever (upto 38.5), sore throat, malaise, muscle pains, mild dyspnea went to GP, given NSAID’s and antibiotics
Developed small red dots especially on legs, gingival bleeding, worsening fatigue
Presented to Santa Cabrini WBC 279,000, Hgb 80 MCV = 90, Plat 25; 60% peripheral blasts
Transferred to JGH.
![Page 4: AN APPROACH TO “BAD BLOOD” AKA ACUTE LEUKEMIA Arif Ali Awan – R2 JGH November 27 th, 2014 IM Teaching](https://reader035.vdocuments.us/reader035/viewer/2022062712/56649c7b5503460f9492e944/html5/thumbnails/4.jpg)
THE FIRST THINGS YOU HAVE TO DO
Make sure patient not in DIC, TLSSymptomatic leukostasis!AML/APL or ALL
![Page 5: AN APPROACH TO “BAD BLOOD” AKA ACUTE LEUKEMIA Arif Ali Awan – R2 JGH November 27 th, 2014 IM Teaching](https://reader035.vdocuments.us/reader035/viewer/2022062712/56649c7b5503460f9492e944/html5/thumbnails/5.jpg)
ACUTE LEUKEMIA
A disease in which immature heterogenous white blood cells multiply or accumulate uncontrollably
Circulating “clonal” white blood cells.
Need to distinguish between AML (60-70%)/APL (5-8% of AML), ALL (~20%)
Hematologic emergency: fatal in weeks to months (Infection, bleeding)
AML: 16000 cases yearly in US, median age 70 y, 3-5/100,000 person-yr
ALL: total 6000 cases yearly in US, minority in adults
![Page 6: AN APPROACH TO “BAD BLOOD” AKA ACUTE LEUKEMIA Arif Ali Awan – R2 JGH November 27 th, 2014 IM Teaching](https://reader035.vdocuments.us/reader035/viewer/2022062712/56649c7b5503460f9492e944/html5/thumbnails/6.jpg)
![Page 7: AN APPROACH TO “BAD BLOOD” AKA ACUTE LEUKEMIA Arif Ali Awan – R2 JGH November 27 th, 2014 IM Teaching](https://reader035.vdocuments.us/reader035/viewer/2022062712/56649c7b5503460f9492e944/html5/thumbnails/7.jpg)
![Page 8: AN APPROACH TO “BAD BLOOD” AKA ACUTE LEUKEMIA Arif Ali Awan – R2 JGH November 27 th, 2014 IM Teaching](https://reader035.vdocuments.us/reader035/viewer/2022062712/56649c7b5503460f9492e944/html5/thumbnails/8.jpg)
![Page 9: AN APPROACH TO “BAD BLOOD” AKA ACUTE LEUKEMIA Arif Ali Awan – R2 JGH November 27 th, 2014 IM Teaching](https://reader035.vdocuments.us/reader035/viewer/2022062712/56649c7b5503460f9492e944/html5/thumbnails/9.jpg)
HISTORY Common: fatigue, infection, bruising, bleeding
Leukostasis: Neuro (CN, altered MS), Resp, CVS
MSK: bone pain
Cardiac history, co-morbidities
Prior transfusions and pregnancies: allo antibodies
Drug allergies
Prior herpes simplex: prophylaxis
Pregnancy/menses: OCP; fertility preservation
Siblings?
Extramedullary: anywhere, gingiva
Skin (leukemia cutis or Sweet syndrome)
Performance status
![Page 10: AN APPROACH TO “BAD BLOOD” AKA ACUTE LEUKEMIA Arif Ali Awan – R2 JGH November 27 th, 2014 IM Teaching](https://reader035.vdocuments.us/reader035/viewer/2022062712/56649c7b5503460f9492e944/html5/thumbnails/10.jpg)
RISK FACTORS
Risk factors: MDS Myeloproliferative disorder Prior chemotherapy IR Trisomy 21 Rare congenital syndromes (Klinefelter’s, Fanconi, dyskeratosis congenita) Smoking RR 1.4 CT scans RR 1.2-1.7 Family history
Not cell phones!
![Page 11: AN APPROACH TO “BAD BLOOD” AKA ACUTE LEUKEMIA Arif Ali Awan – R2 JGH November 27 th, 2014 IM Teaching](https://reader035.vdocuments.us/reader035/viewer/2022062712/56649c7b5503460f9492e944/html5/thumbnails/11.jpg)
PHYSICAL EXAM
Fever: treat as infection
Eyes: hemorrhages and or exudates up to half have ocular involvement.
Oropharynx: gingival involvement, dental caries, oral thrust
Organomegaly and LNs: uncommon in AML - think of ALL or CML in blast crises
Neuro: CN palsies, Altered MS.
Skin: pallor, infiltrative lesions, petechiae and echymoses, leukemia cutis (10-15%), Sweet Syndrome
![Page 12: AN APPROACH TO “BAD BLOOD” AKA ACUTE LEUKEMIA Arif Ali Awan – R2 JGH November 27 th, 2014 IM Teaching](https://reader035.vdocuments.us/reader035/viewer/2022062712/56649c7b5503460f9492e944/html5/thumbnails/12.jpg)
LEUKEMIA CUTIS
![Page 13: AN APPROACH TO “BAD BLOOD” AKA ACUTE LEUKEMIA Arif Ali Awan – R2 JGH November 27 th, 2014 IM Teaching](https://reader035.vdocuments.us/reader035/viewer/2022062712/56649c7b5503460f9492e944/html5/thumbnails/13.jpg)
SWEET SYNDROME AKA ACUTE FEBRILE NEUTROPHILIC DERMATOSIS
![Page 14: AN APPROACH TO “BAD BLOOD” AKA ACUTE LEUKEMIA Arif Ali Awan – R2 JGH November 27 th, 2014 IM Teaching](https://reader035.vdocuments.us/reader035/viewer/2022062712/56649c7b5503460f9492e944/html5/thumbnails/14.jpg)
AML CNS INVOLVEMEMENT
uncommon ( 5-7%): high circulating blast count, M5
defer LP if high blast count and asymptomatic to avoid contamination defer LP to consolidation
![Page 15: AN APPROACH TO “BAD BLOOD” AKA ACUTE LEUKEMIA Arif Ali Awan – R2 JGH November 27 th, 2014 IM Teaching](https://reader035.vdocuments.us/reader035/viewer/2022062712/56649c7b5503460f9492e944/html5/thumbnails/15.jpg)
IDENTIFYING LINEAGE: AML/APL, ALL Morphology not always helpful Flow cytometry Immunostains Cytogenetics
![Page 16: AN APPROACH TO “BAD BLOOD” AKA ACUTE LEUKEMIA Arif Ali Awan – R2 JGH November 27 th, 2014 IM Teaching](https://reader035.vdocuments.us/reader035/viewer/2022062712/56649c7b5503460f9492e944/html5/thumbnails/16.jpg)
AML DIAGNOSIS
Blood and marrow (aspirate and biopsy)
Auer rods: rod like filaments of aggregated primary azurophilic granules (most seen in M1 and M2)
> 20% blasts in BM/peripheral or recurrent cytogenetic abnormality
Special stains distinguish myeloid (MPO) from lymphoid (TdT)
Flow cytometry: help to distinguish lymphoid from myeloid (CD13, 33, 34, 117); establishes maturation
DO CYTOGENETICS!
![Page 17: AN APPROACH TO “BAD BLOOD” AKA ACUTE LEUKEMIA Arif Ali Awan – R2 JGH November 27 th, 2014 IM Teaching](https://reader035.vdocuments.us/reader035/viewer/2022062712/56649c7b5503460f9492e944/html5/thumbnails/17.jpg)
ROUTINE LAB TESTING
CBC with differential and blood film
BUN, creatinine, lytes, uric acid, glucose
Liver enzymes, LDH
calcium profile
PT, PTT, fibrinogen, FDPs or D dimers
flow cytometry if blasts in blood
Beta-HCG
Type and Screen
Defer HSCT testing: HLA, CMV, Hep A/B/C/HIV/HTLV
![Page 18: AN APPROACH TO “BAD BLOOD” AKA ACUTE LEUKEMIA Arif Ali Awan – R2 JGH November 27 th, 2014 IM Teaching](https://reader035.vdocuments.us/reader035/viewer/2022062712/56649c7b5503460f9492e944/html5/thumbnails/18.jpg)
LABORATORY FINDINGS
WBC: 20% > 100,000, 50% normal or reduced
Pancytopenia
Watch out for tumor lysis syndrome (hypoCA, HyperPhos, Acidosis, hyperK, increased LDH, increased Uric Acid, renal failure).
![Page 19: AN APPROACH TO “BAD BLOOD” AKA ACUTE LEUKEMIA Arif Ali Awan – R2 JGH November 27 th, 2014 IM Teaching](https://reader035.vdocuments.us/reader035/viewer/2022062712/56649c7b5503460f9492e944/html5/thumbnails/19.jpg)
ADDITIONAL INTERVENTIONS CXR
ECG
TTE if risk factors
LP if symptomatic
BM asp and biopsy with cytogenetics and flow cytometry (subclassification, prognosis, tailoring treatment): KIT, FLT3, NPM1, CEBPA
Broviac placement
Fertility preservation
Dentistry consultation if poor oral hygiene
Oncology/transplant nurse
Psychosocial support
![Page 20: AN APPROACH TO “BAD BLOOD” AKA ACUTE LEUKEMIA Arif Ali Awan – R2 JGH November 27 th, 2014 IM Teaching](https://reader035.vdocuments.us/reader035/viewer/2022062712/56649c7b5503460f9492e944/html5/thumbnails/20.jpg)
AML - FAB
FAB subgroups based on the predominant cell type and to define the leukemia’s cell position in the maturation sequence of that specific lineage, less common use nowadays
M0-M7
M0 Minimal differentiation (3%)M1 Without maturation (15–20%)M2 Maturation (25–30%)M3 Acute promyelocytic leukemia (5–10%) M4 Acute myelomonocytic leukemia (20%) M4Eo Acute myelomonocytic leukemia with abnormal eosinophils (5–10%)M5 Acute monocytic leukemia (2–9%)M6 Erythroleukemia (3–5%)M7 Acute megakaryocytic leukemia (5%)
![Page 21: AN APPROACH TO “BAD BLOOD” AKA ACUTE LEUKEMIA Arif Ali Awan – R2 JGH November 27 th, 2014 IM Teaching](https://reader035.vdocuments.us/reader035/viewer/2022062712/56649c7b5503460f9492e944/html5/thumbnails/21.jpg)
AML
![Page 22: AN APPROACH TO “BAD BLOOD” AKA ACUTE LEUKEMIA Arif Ali Awan – R2 JGH November 27 th, 2014 IM Teaching](https://reader035.vdocuments.us/reader035/viewer/2022062712/56649c7b5503460f9492e944/html5/thumbnails/22.jpg)
WHO
AML with recurrent genetic abnormalities t(8;21)- AML/ETO With abnormal bone marrow eosinophils and inv16 or t(16;16) 11q23 abnormalities
AML with multilineage dysplasia
AML and MDS-therapy related
AML not otherwise categorized
++ atleast 20 different subtypes
![Page 23: AN APPROACH TO “BAD BLOOD” AKA ACUTE LEUKEMIA Arif Ali Awan – R2 JGH November 27 th, 2014 IM Teaching](https://reader035.vdocuments.us/reader035/viewer/2022062712/56649c7b5503460f9492e944/html5/thumbnails/23.jpg)
AML TREATMENT
Goal: stabilize patient and then rapid restoration of normal BM function.
Induce Remission: Induction: reduces leukemia cell population from 1012 to 109 (MRD)
Prevent Relapse: Consolidation: 1-3 or more courses of chemo or BMT to eradicate residual leukemia and allow for cure
Complete Remission: normal blood counts (ANC>1000, plt > 100,000, no pRBC transfusion needs) and BM cellularity with < 5% blasts without leukemic phenotype
Cure?: relapse and death rates low after 3-4 years remission; 40% age < 60
Clinical trials
![Page 24: AN APPROACH TO “BAD BLOOD” AKA ACUTE LEUKEMIA Arif Ali Awan – R2 JGH November 27 th, 2014 IM Teaching](https://reader035.vdocuments.us/reader035/viewer/2022062712/56649c7b5503460f9492e944/html5/thumbnails/24.jpg)
AML TREATMENT INDUCTION 7+3 1) Cytarabine (Ara C )
-continuous infusion x 7 days
-<60 yo 200 mg/m2; >60 yo 100 mg/m2
- Myelosuppresion: biphasic nadir 7-9 D, 15-24D, Rash, conjunctivitis, Mod. N/V, increased LFT’s, ulceration, neurotoxicity (cerebellar dysfunction)
2) Anthracycline
-Daunorubicin 60-90 mg/m2 IV x 3 days
-Dose reduce with hepatic dysfunction (bilirubin)
- Myelosuppresion: nadir 10-14 D, cardiac toxicity, mucositis, red/orange urine, Mod. N/V, increased LFT’s,
?? D14 Marrow
![Page 25: AN APPROACH TO “BAD BLOOD” AKA ACUTE LEUKEMIA Arif Ali Awan – R2 JGH November 27 th, 2014 IM Teaching](https://reader035.vdocuments.us/reader035/viewer/2022062712/56649c7b5503460f9492e944/html5/thumbnails/25.jpg)
SUPPORTIVE CARE DURING INDUCTION Febrile Neutropenia: treat find source otherwise prophylaxis (Levofloxacin) RR 0.66 reduced mortality. NNT 30’ 60% identified source, 6% mortality (15% of cases fungal, 15% mixed, 5% bacteria)
IPA prophylaxis posaconazole NNT 20 mortality
Herpes Simplex Prophylaxis
Nutrition
HLA matched CMV neg, irradiated, leukodepleted transfusions (plt > 50000 APL)
?G-CSF no survival benefi
TLS: Allopurinal nearly all; Rasburicase if WBC > 100,000, T-ALL but not if G6PD def.
Beware transfusions with leukostasis.
Psychosocial
![Page 26: AN APPROACH TO “BAD BLOOD” AKA ACUTE LEUKEMIA Arif Ali Awan – R2 JGH November 27 th, 2014 IM Teaching](https://reader035.vdocuments.us/reader035/viewer/2022062712/56649c7b5503460f9492e944/html5/thumbnails/26.jpg)
AML TREATMENT CONSOLIDATION High dose cytarabine/Ara-C (HiDAC)
3g/m2 x 6 doses
For 3-4 cycles
No proven role for maintenance therapy in AML compared to ALL
If relapse: salvage chemotherapy, re-induction, clinical trial, ?autologous transplant
![Page 27: AN APPROACH TO “BAD BLOOD” AKA ACUTE LEUKEMIA Arif Ali Awan – R2 JGH November 27 th, 2014 IM Teaching](https://reader035.vdocuments.us/reader035/viewer/2022062712/56649c7b5503460f9492e944/html5/thumbnails/27.jpg)
HSCT/TRANSPLANT
Allogenic matched related donor better than unrelated donor
Unfavourable prognosis – 20% increased survival 27 vs 7 % at 5 year
Intermediate risk – 6 to 10% increased survival
![Page 28: AN APPROACH TO “BAD BLOOD” AKA ACUTE LEUKEMIA Arif Ali Awan – R2 JGH November 27 th, 2014 IM Teaching](https://reader035.vdocuments.us/reader035/viewer/2022062712/56649c7b5503460f9492e944/html5/thumbnails/28.jpg)
COMPLICATIONS: LEUKOSTASIS WBC > 50,000 (AML > ALL)
Neurological: visual disturbance, headache/dizziness, TIA/CVA
CVS: MI
Resp: dyspnea, infiltrate on chest X-ray
Treatment: hydroxyurea, chemo, leukapheresis
![Page 29: AN APPROACH TO “BAD BLOOD” AKA ACUTE LEUKEMIA Arif Ali Awan – R2 JGH November 27 th, 2014 IM Teaching](https://reader035.vdocuments.us/reader035/viewer/2022062712/56649c7b5503460f9492e944/html5/thumbnails/29.jpg)
TUMOR LYSIS SYNDROME
ALL > AML
First sign incr. LDH, low Ca
Then hyperkalemia, hyperphosphatemia, increased uric acid, renal failure, cardiac arrhythmias
![Page 30: AN APPROACH TO “BAD BLOOD” AKA ACUTE LEUKEMIA Arif Ali Awan – R2 JGH November 27 th, 2014 IM Teaching](https://reader035.vdocuments.us/reader035/viewer/2022062712/56649c7b5503460f9492e944/html5/thumbnails/30.jpg)
AML PROGNOSIS
Age (> or <60); > 60 worse secondary AML blast count > 100,000 response to induction chemotherapy APL better prognosis
![Page 31: AN APPROACH TO “BAD BLOOD” AKA ACUTE LEUKEMIA Arif Ali Awan – R2 JGH November 27 th, 2014 IM Teaching](https://reader035.vdocuments.us/reader035/viewer/2022062712/56649c7b5503460f9492e944/html5/thumbnails/31.jpg)
CYTOGENETICS
Karyotype Molecular modifications
Favourable t(15,17), t(8,21); inv(16)/t(16:16)
NPM1 (FLT3 neg), CEBPA (biallelic)
Intermediate
Normal; includes -y, +8, +21, +22,
CEBPA
Poor -5/del(5q), -7/del (7q), t(6,9), 11q23, 3 or more abnormalities
FLT3
Over 23 genes mutated
![Page 32: AN APPROACH TO “BAD BLOOD” AKA ACUTE LEUKEMIA Arif Ali Awan – R2 JGH November 27 th, 2014 IM Teaching](https://reader035.vdocuments.us/reader035/viewer/2022062712/56649c7b5503460f9492e944/html5/thumbnails/32.jpg)
AML PROGNOSIS
55-70% achieve CR with induction
50-70% will relapse during the first 18-24 months
allogeneic transplant an option in select few with sibling (preferable)
no role for maintenance chemotherapy
![Page 33: AN APPROACH TO “BAD BLOOD” AKA ACUTE LEUKEMIA Arif Ali Awan – R2 JGH November 27 th, 2014 IM Teaching](https://reader035.vdocuments.us/reader035/viewer/2022062712/56649c7b5503460f9492e944/html5/thumbnails/33.jpg)
APL
Excellent prognosis once treatment started (higher mortality prior), younger ~ 30’s
Remember DIC/severe thrombocytopenia/CNS bleeding
t (15;17); t(11;17): PML-RAR α aberrant fusion protein blocks myeloid differentiation.
Treated with:
Induction: All-trans retinoic acid (ATRA) + anthracycline (nearly all patients CR)
Consolidation: ATRA or Arsenic trioxide (ATO)
Maintainence: ATRA, 6-Mercapto-purine, oral methotrexate
Auto-HSCT if relapse.
![Page 34: AN APPROACH TO “BAD BLOOD” AKA ACUTE LEUKEMIA Arif Ali Awan – R2 JGH November 27 th, 2014 IM Teaching](https://reader035.vdocuments.us/reader035/viewer/2022062712/56649c7b5503460f9492e944/html5/thumbnails/34.jpg)
APL - 2
Watch out for differentiation syndrome (25-40%): fever, edema, stomatitis, Hypotension dyspnea, ARDS renal/liver failure Treated with high dose steroids (Dex 10 mg IV BID), temporary cessation ATRA/ATO
Other AE: electrolyte imbalances, QT prolongation, rash, pain, increased LFT’s, hearing loss (ATO)
![Page 35: AN APPROACH TO “BAD BLOOD” AKA ACUTE LEUKEMIA Arif Ali Awan – R2 JGH November 27 th, 2014 IM Teaching](https://reader035.vdocuments.us/reader035/viewer/2022062712/56649c7b5503460f9492e944/html5/thumbnails/35.jpg)
ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)Only ~ 1000 adult cases/year in US
Similar presentation to AML
Hepatosplenomegaly and LNs more common
Leukocytosis less common
CNS involvement (15%) and relapse more common
Mediastinal mass in T cell ALL: CXR, CT chest
TLS more common than AML, can be spontaneous
TdT stain (ALL), MPO (AML)
LP, testicular exam
Philadelphia chromosome
![Page 36: AN APPROACH TO “BAD BLOOD” AKA ACUTE LEUKEMIA Arif Ali Awan – R2 JGH November 27 th, 2014 IM Teaching](https://reader035.vdocuments.us/reader035/viewer/2022062712/56649c7b5503460f9492e944/html5/thumbnails/36.jpg)
ALLB-cells (~80%): CD10, 19, 20
L1=Early Precursor B-ALL
subtype represents 25-30% of adult cases
L2= Pre-B ALL
representing 70% of cases
L3/Burkitt’s=B-ALL
subtype accounts for 1-2% of adult cases
T-ALL (~ 20%): CD2, 3, 5, 7, 4, 8, 38
Particularly aggressive
![Page 37: AN APPROACH TO “BAD BLOOD” AKA ACUTE LEUKEMIA Arif Ali Awan – R2 JGH November 27 th, 2014 IM Teaching](https://reader035.vdocuments.us/reader035/viewer/2022062712/56649c7b5503460f9492e944/html5/thumbnails/37.jpg)
ALL TREATMENT
Borrowed from pediatric protocols
Overall survival 40%
PH chromosome ALL in 30%: poor prognosis
treatment 4 components over 2-3 years: Induction, consolidation, CNS prophylaxis and maintenance Mainly outpatient Allo BMT for PH + ALL or relapsed disease
Prognosis:
Good: children, pre-B WBC < 30,000, T-ALL < 100,000, rapid CR, t(12,21), hyperdiploidy
Bad: Ph chromosome changing with TKI-inhibitors, t(4,11), MLL/11q34 translocation
![Page 38: AN APPROACH TO “BAD BLOOD” AKA ACUTE LEUKEMIA Arif Ali Awan – R2 JGH November 27 th, 2014 IM Teaching](https://reader035.vdocuments.us/reader035/viewer/2022062712/56649c7b5503460f9492e944/html5/thumbnails/38.jpg)
BACK TO OUR PATIENT
AML with leukemia cutis, FLT3 negative, intermediate cytogenetics
Given hydroxyurea (4g/day) initially
LP positive blasts
Induction chemotherapy complicated by:
1) Febrile neutropenia secondary CLA-BSI with VRE bacteremia
2) Severe Mucositis: MMW, pink lady, dilaudid
3) 15% weight loss: nutrition
4) Mild increased in liver enzymes
Day 28 bone marrow: CR
Received consolidation
Awaiting Allo-HSCT
![Page 39: AN APPROACH TO “BAD BLOOD” AKA ACUTE LEUKEMIA Arif Ali Awan – R2 JGH November 27 th, 2014 IM Teaching](https://reader035.vdocuments.us/reader035/viewer/2022062712/56649c7b5503460f9492e944/html5/thumbnails/39.jpg)
FUTURE DIRECTIONS
Autologous Chimeric antigen receptor T-cells targeting CD19
Used in relapsed/refractory ALL: CR 90%, sustained response 67% of patients and response seen up to 24 months.
![Page 40: AN APPROACH TO “BAD BLOOD” AKA ACUTE LEUKEMIA Arif Ali Awan – R2 JGH November 27 th, 2014 IM Teaching](https://reader035.vdocuments.us/reader035/viewer/2022062712/56649c7b5503460f9492e944/html5/thumbnails/40.jpg)
SUMMARY
Acute leukemia: emergency
AML/APL vs ALL
Leukostasis: symptomatic ?urgent treatment
Treatment: Feb. Neut, TLS, transfusions, Anti-microbial prophylaxis
Watch out for adverse effects due to chemotherapy
![Page 41: AN APPROACH TO “BAD BLOOD” AKA ACUTE LEUKEMIA Arif Ali Awan – R2 JGH November 27 th, 2014 IM Teaching](https://reader035.vdocuments.us/reader035/viewer/2022062712/56649c7b5503460f9492e944/html5/thumbnails/41.jpg)
REFERENCES
DynaMed: AML, ALL, APL
Pocket Oncology 2014